Total Payments
$162,427
2024 Payments
$43,299
Companies
20
Transactions
112
Medicare Patients
843
Medicare Billing
$152,082
Payment Breakdown by Category
Consulting$120,414 (74.1%)
Other$25,380 (15.6%)
Travel$9,594 (5.9%)
Research$4,533 (2.8%)
Food & Beverage$2,505 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $120,414 | 47 | 74.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,300 | 2 | 11.3% |
| Travel and Lodging | $9,594 | 23 | 5.9% |
| Honoraria | $7,080 | 4 | 4.4% |
| Unspecified | $4,533 | 2 | 2.8% |
| Food and Beverage | $2,505 | 34 | 1.5% |
Payments by Type
General
$157,894
110 transactions
Research
$4,533
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70,622 | 39 | $0 (2024) |
| Daiichi Sankyo Inc. | $17,966 | 17 | $0 (2024) |
| Lilly USA, LLC | $9,658 | 13 | $0 (2019) |
| BeiGene USA, Inc. | $8,042 | 5 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,236 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $6,908 | 4 | $0 (2023) |
| Taiho Oncology, Inc. | $5,797 | 5 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $4,745 | 2 | $0 (2022) |
| Eli Lilly and Company | $4,668 | 4 | $0 (2018) |
| AstraZeneca UK Limited | $3,768 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,299 | 37 | Merck Sharp & Dohme LLC ($18,804) |
| 2023 | $11,720 | 5 | Merck Sharp & Dohme LLC ($6,100) |
| 2022 | $19,197 | 4 | Merck Sharp & Dohme LLC ($12,200) |
| 2021 | $34,161 | 11 | Merck Sharp & Dohme Corporation ($19,999) |
| 2020 | $9,697 | 13 | Daiichi Sankyo Inc. ($5,167) |
| 2019 | $12,242 | 13 | Daiichi Sankyo Inc. ($6,309) |
| 2018 | $16,418 | 17 | Lilly USA, LLC ($5,524) |
| 2017 | $15,691 | 12 | Merck Sharp & Dohme Corporation ($7,551) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $215.00 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $62.57 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $41.38 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $124.59 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $49.83 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $111.78 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | Cash or cash equivalent | $94.72 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $411.90 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $235.00 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $225.00 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 08/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $5,185.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,372.50 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2024 | Fosun Pharma USA Inc. | — | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Fosun Pharma USA Inc. | — | Food and Beverage | In-kind items and services | $187.29 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Travel and Lodging | In-kind items and services | $4,500.00 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RANDOMIZED PHASE 2 TRIAL EVALUATING ALTERNATIVE RAMUCIRUMAB DOSES IN COMBINATION WITH PACLITAXEL IN SECOND-LINE METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Eli Lilly and Company | $2,316 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY OF CAPECITABINE AND CISPLATIN WITH OR WITHOUT RAMUCIRUMAB AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA-RAINFALL | Eli Lilly and Company | $2,217 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 170 | 303 | $200,083 | $34,576 |
| 2022 | 6 | 251 | 472 | $251,147 | $46,369 |
| 2021 | 4 | 208 | 341 | $181,417 | $38,369 |
| 2020 | 5 | 214 | 350 | $141,383 | $32,768 |
Total Patients
843
Total Services
1,466
Medicare Billing
$152,082
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 44 | 88 | $63,800 | $10,553 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 84 | $61,060 | $9,977 | 16.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 58 | $23,774 | $4,834 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $20,351 | $3,475 | 17.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $19,639 | $3,403 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 28 | $11,459 | $2,334 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 83 | $59,139 | $10,081 | 17.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 41 | 78 | $55,591 | $9,420 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 28 | 62 | $24,838 | $5,159 | 20.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 57 | $22,743 | $4,674 | 20.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 76 | $21,128 | $4,540 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 50 | $19,998 | $4,153 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $24,188 | $4,125 | 17.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $19,026 | $3,219 | 16.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 16 | 16 | $4,496 | $998.06 | 22.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 59 | 90 | $53,766 | $10,480 | 19.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 67 | $41,531 | $8,587 | 20.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $20,704 | $4,535 | 21.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 51 | $20,349 | $4,409 | 21.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 47 | $16,113 | $3,652 | 22.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $16,910 | $3,563 | 21.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 36 | $12,044 | $3,143 | 26.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 130 | $62,912 | $12,509 | 19.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 68 | 68 | $39,606 | $10,078 | 25.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 48 | 111 | $30,417 | $7,663 | 25.2% |
About Peter Enzinger, DR
Peter Enzinger, DR is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710954391.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Peter Enzinger, DR has received a total of $162,427 in payments from pharmaceutical and medical device companies, with $43,299 received in 2024. These payments were reported across 112 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($120,414).
As a Medicare-enrolled provider, Enzinger has provided services to 843 Medicare beneficiaries, totaling 1,466 services with total Medicare billing of $152,082. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 03/02/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1710954391
Products in Payments
- KEYTRUDA (Biological) $41,537
- Enhertu (Drug) $14,216
- CYRAMZA (Drug) $8,801
- TEVIMBRA (Drug) $8,042
- Developmental Compound $6,784
- Asparlas (Drug) $3,740
- Lonsurf (Drug) $3,157
- ILARIS (Biological) $2,813
- Abraxane (Drug) $2,579
- Lenvima (Drug) $2,355
- Tislelizumab (Drug) $109.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701